IL-8 and CD32<sup>+</sup> macrophages should now be explored as targets in combination with GBM immunotherapies, especially for patients whose tumors present with radiographic contact with the ventricular-subventricular zone stem cell niche. This evidence concerns the gene CXCL8 and glioblastoma.